Who
Gwen A. Melincoff
Director
Company insider
Files Form 4 as: Director, Protalix BioTherapeutics, Inc. (DE); Director, Gain Therapeutics; Director, Collegium Pharmaceutical; Director, Soleno Therapeutics; Director, Tobira Therapeutics.
In numbers
- Trades disclosed
- 41
- Buys
- 1
- Sells
- 0
- Bought
- $15K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 4 May 2015
- Last trade
- 3 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 3 Sep 2026filed 4 Sep 2026 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —8,500 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Sep 2025filed 4 Sep 2025 | PLX Protalix BioTherapeutics, Inc. (DE)Biotechnology | SEC FORM 4 Code A | —7,500 | filing |
| 24 Jun 2025filed 25 Jun 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 24 Jun 2024filed 26 Jun 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 May 2024filed 16 May 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —7,693 at $0.00 | filing |
| 29 Sep 2023filed 3 Oct 2023 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —61,676 at $0.00 | filing |
| 23 Jun 2023filed 26 Jun 2023 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 26 May 2023filed 26 May 2023 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 25 May 2023filed 26 May 2023 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code A | —2,666 at $0.00 | filing |
| 18 May 2023filed 19 May 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —9,792 at $0.00 | filing |
| 20 Sep 2022filed 22 Sep 2022 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 7 Sep 2022filed 9 Sep 2022 | PLX Protalix BioTherapeutics, Inc. (DE)option or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Jun 2022filed 14 Oct 2022 | Soleno Therapeuticsoption or derivative | SEC FORM 4 Code A | —2,666 at $0.00 | filing |
| 19 May 2022filed 23 May 2022 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —14,035 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.